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Whole-genome sequencing of Mycobacterium tuberculosis as an 
epidemiological marker
DNA ﬁ ngerprinting of Mycobacterium tuberculosis 
has revolutionised the study of the transmission of 
tuberculosis. Since the early 1990s, IS6110 restriction 
fragment length polymorphism (RFLP) typing and 
variable number of tandem repeat (VNTR) typing have 
progressed and are being used to answer longstanding 
epidemiological questions.1 DNA ﬁ ngerprinting 
of M tuberculosis isolates enables the visualisation 
of transmission and allows a much more sensitive 
investigation of this important aspect of tuberculosis 
control. Although having these possibilities is an 
advantage to tuberculosis control in daily practice, the 
ﬁ ndings of possible epidemiological links as shown with 
DNA ﬁ ngerprinting are only partly conﬁ rmed through 
the standard epidemiological investigation by patient 
interviews. As a result, DNA ﬁ ngerprinting is used to 
indicate possible epidemiological links, but the veriﬁ cation 
of these links is dependent on whether we can understand 
how transmission occurred; if contact between the 
patients is not thought to be possible, transmission is 
ruled out. This veriﬁ cation, however, does not include 
incidental contacts in the public domain and might lead to 
an underestimation of active transmission. Nevertheless, 
with RFLP or VNTR typing, transmissions can often be 
excluded and possible links are at least indicated much 
more sensitively than through interviews alone.2 Some of 
the uncertainties, however, about the usefulness of RFLP 
or VNTR typing are also caused by the slow turnover of 
these markers;  RFLP typing has a half-life of 3–4 years3 
and the change in patterns for VNTR typing has not yet 
been established accurately. However, most M tuberculosis 
strains retain their RFLP or VNTR proﬁ les during trans mis-
sion and the sources—eg, primary, secondary, or tertiary—
cannot be distinguished within DNA ﬁ ngerprint clusters. 
In 2010 and 2011, the ﬁ rst results of M tuberculosis 
DNA ﬁ ngerprinting with whole-genome sequencing 
(WGS) were reported and it became apparent that this 
new approach has a higher resolution than conventional 
typing.4,5 Clusters of cases according to RFLP or VNTR typing 
were subdivided into actual transmission chains and this 
new information was more in agreement with the contact 
tracing information. Previous studies of the usefulness of 
WGS have been retrospective, but in Timothy Walker and 
colleagues’ study in Oxfordshire, UK,6 WGS was applied in 
the ﬁ rst line to ascertain clustering of tuberculosis cases 
and to quantify active transmission. This WGS was done 
with a pairwise determination of the number of single 
nucleotide polymorphisms (SNPs) separating the isolates; 
a diﬀ erence of a maximum of 12 SNPs was applied to 
rule in a possible transmission. Although this approach is 
elegant and valid there are still further considerations in the 
validation process of WGS. As for RFLP and VNTR typing, 
the usefulness of WGS depends on the population structure 
of M tuberculosis in the setting in which it is used.7 In Walker 
and colleagues, only in a subset of the pairs of cases with 
fewer than 12 SNPs diﬀ erence was an epidemiological link 
conﬁ rmed with interviews and transmission judged likely; 
these ﬁ ndings are in agreement with those of an earlier 
study in Amsterdam.8 Does this indicate that strains with 
little or no diﬀ erence are circulating in these areas without 
any epidemiological link between the respective cases? Or 
are we again, and this time with a more accurate and higher 
resolution marker, not able to understand how trans-
mission of tuberculosis occurred? Is it simply impossible to 
conﬁ rm transmission through interviews with patients? 
This apparent lack of resolution in typing is also related 
to the remarkable genomic stability of M tuberculosis. In a 
study in the UK, a turnover of 0·5 SNPs per genome per year 
was noted, whereas in the Netherlands a highly similar rate 
of change of 0·36 SNPs was found.8,9 
Another major concern that has not been suﬃ  ciently 
addressed and investigated generally is that M tuberculosis 
isolates are not at all homogeneous populations. They 
comprise several populations with diﬀ erent SNP proﬁ les.10 
With the current WGS techniques only the SNP proﬁ le in 
the predominating population is visualised; however, this 
predominance might shift when the strain is passed on to 
another person.
In view of the concerns described above, WGS is also 
not an ideal epidemiological marker, but still undoubtedly 
a major step forward  in DNA ﬁ ngerprinting compared 
with the conventional RFLP and VNTR typing. In the 
molecular epidemiology of tuberculosis it would be ideal if 
at each transmission a minor, but recognisable, diﬀ erence 
occurred in the DNA proﬁ le of M tuberculosis. Such a 
diﬀ erence would enable the deduction of all transmission 
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forks and the separation of transmission for subsequent 
sources in a chain of transmission in time. Unfortunately, 
the current WGS is also not a perfect method.
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Should we pursue pulmonary vasodilation in patients 
with COPD?
Pulmonary hypertension is a pathophysiological disorder 
deﬁ ned as an increase in pulmonary arterial pressure, 
as assessed by right heart ca theterisation (mean 
pressure ≥25 mm Hg at rest). Pulmonary hypertension 
can arise in various clinical disorders, which have been 
classiﬁ ed by WHO into ﬁ ve clinical groups, on the basis 
of mechanisms, with diﬀ erent pathogenic, prognostic, 
and therapeutic features.1 The ﬁ rst group is deﬁ ned as 
pulmonary arterial hypertension, whereas the third 
group encompasses pulmonary hypertension due to 
lung diseases or hypoxaemia, including hypertension 
due to chronic obstructive pulmonary disease (COPD), 
interstitial lung disease, and sleep-disordered breathing. 
In patients with COPD, the presence of COPD-associated 
pulmonary hypertension has been linked with reduced 
exercise capacity, impaired quality of life, and increased 
risk of mortality.2,3 Therefore, interventions that alleviate 
COPD-associated pulmonary hypertension are needed 
to improve symptoms, prevent right heart failure, and 
prolong survival.
Prostanoids, endothelin receptor antagonists, and 
phosphodiesterase type-5 (PDE5) inhibitors are the main 
treatment options for patients with pulmonary arterial 
hypertension.1 PDE5 inhibitors increase cyclic guanosine 
monophosphate (GMP), the ﬁ nal mediator in the nitric 
oxide pathway, in smooth muscle cells of the pulmonary 
artery, causing pulmonary arterial vasodilation. PDE5 
inhibitors have proven eﬀ ectiveness in pulmonary 
arterial hypertension, enhancing exercise capacity and 
quality of life. However, in patients with COPD-associated 
pulmonary hypertension, treatment with the short-acting 
PDE5 inhibitor sildenaﬁ l did not improve exercise capacity 
or quality of life.4 In The Lancet Respiratory Medicine, Andrew 
Goudie and colleagues investigate whether the long-acting 
PDE5 inhibitor tadalaﬁ l is beneﬁ cial in patients with severe 
COPD and mild pulmonary hypertension.5 Findings from 
this randomised, double-blind, parallel-group, placebo-
controlled trial show that, compared with placebo, 
tadalaﬁ l did not improve exercise capacity after 12 weeks, 
as measured by the primary endpoint of 6 minute walking 
distance (between-group diﬀ erence 0·5 m, 95% CI –11·6 
to 12·5; p=0·937). Additionally, tadalaﬁ l did not improve 
quality of life, lung function (spirometry and diﬀ usion of 
lung carbon monoxide [DLCO]), or serum B-natriuretic 
peptide, a biomarker associated with worse prognosis in 
patients with pulmonary hypertension. 
Why was tadalaﬁ l ineﬀ ective in patients with COPD-
associated pulmonary hypertension in this trial? 
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